Prevalence and determinants of poor glycemic control among diabetic chronic kidney disease patients on maintenance hemodialysis in Tanzania

Emmanuel Arthur Mfundo^{1,2}, Alphonce Ignace Marealle², Goodluck G. Nyondo³, Martine A. Manguzu², Deus Buma⁴, Peter Kunambi⁵, Ritah F. Mutagonda^{2#}

Authors' affiliations:

¹Quality Assurance Department, National Health Insurance Fund, NSSF-Kaloleni Plaza P.O Box 16110 Arusha.

² Department of Clinical Pharmacy and Pharmacology, Muhimbili University of Health and Allied Sciences, P.O Box 65013, Dar es Salaam.

³Department of Medicinal Chemistry, School of Pharmacy, Muhimbili University of Health and Allied Sciences, P.O Box 65013, Dar es Salaam, Tanzania.

⁴Department of Clinical Research, Training and Consultancy, Muhimbili National Hospital, P.O Box 65000 Dar es Salaam.

⁵Department of Clinical Pharmacology, Muhimbili University of Health and Allied Sciences, P.O Box 65001, Dar es Salaam.

#Corresponding author: Dr. Ritah F. Mutagonda

Email: ritah.mutagonda@muhas.ac.tz Mobile number: +255 713 816 481

ABSTRACT

Background: Poor glycemic control in diabetic chronic kidney disease (CKD) patients on maintenance hemodialysis is of great challenge, resulting in increased risk of morbidity and mortality. This study aimed to determine the prevalence and determinants of poor glycemic control among diabetic CKD patients on maintenance hemodialysis.

Methodology: A cross-sectional study was conducted in 12 dialysis centers located in four regions of Tanzania from March to June 2023. The study population was diabetic CKD patients above 18 years on maintenance hemodialysis for three months or more. A consecutive sampling technique was used for patient recruitment, and a semi-structured questionnaire was used to collect data. The primary outcome was poor glycemic control which was considered when glycated hemoglobin (HbA1c) levels were < 6% or >8%. Statistical Package for Social Sciences (SPSS) version 23 was used for data analysis. Univariate and multivariable regression models were used to evaluate the determinants of poor glycemic control. A p-value <0.05 was considered statistically significant. **Results:** Out of 233 enrolled patients, the overall prevalence of poor glycemic control was 55.4%, whereby 27.0% had HbA1c <6% and 28.33% had HbA1c >8%. A high risk of HbA1c >8% was observed among patients who were on antidiabetic medication (2.16 (95% CI: 1.02– 2.48) p = 0.035) and those attending dialysis sessions less than 3 times a week (1.59 (95% CI: 1.02– 2.48) p = 0.04). While the predictor of HbA1c <6% was the type of dialyzer used (0.57 (95% CI 0.36 – 0.87) p = 0.020).

Conclusion: There is a high prevalence of poor glycemic control among diabetic CKD patients. Patients who were on antidiabetic medication and those who had less than three dialysis sessions had a high risk of HbA1c >8%. In contrast, those dialyzed using glucose-free dialysates had a high risk of HbA1c <6%.

Keywords: Diabetes mellitus, Chronic Kidney Disease, Glycemic control, Hemodialysis, Antidiabetic medications, Glycated hemoglobin

1 Background

Glycemic control in diabetic chronic kidney disease (CKD) patients is a great challenge due to altered glucose homeostasis, gluconeogenesis, tubular glucose reabsorption and inaccuracy of glycemic regulation metrics (1). Furthermore, changed renal pharmacokinetics of antihyperglycemic agents (AHA), uremic milieu, and dialysis therapy also contribute to this challenge (2). Based on the severe risk of hyperglycemia and hypoglycemia in patients with diabetic end-stage renal disease (ESRD), glycemic control is of paramount importance.

A study conducted in India showed a higher frequency of hypoglycemia in diabetic CKD patients 8 compared to those without CKD. Moreover, a high mortality rate was associated with 9 hypoglycemia among these patients (3). In addition, a significant association has been reported 10 11 between poor glycemic control and low survival rates in diabetic CKD patients on hemodialysis compared to individuals with proper glycemic control. Notably, cardiovascular and infections were 12 significant causes of death in this patient population (4). Furthermore, alteration in metabolism 13 and elimination of antihyperglycemic agents (AHA) contribute to the incidence of hypoglycemia 14 in diabetic hemodialysis patients (3,5). 15

A study conducted in Canada reported a 54% prevalence of poor glycemic control among diabetic 16 patients undergoing hemodialysis (6). In addition, another study conducted in Tanzania reported 17 glycemic control to be positively linked with adherence to antidiabetic medications, where 18 19 optimum glycemic control was achieved in patients with good adherence to medication (7). In 20 contrast, poor glycemic control is associated with non-adherence to antidiabetic medications, leading to hyperglycemia-related complications such as coronary artery disease (CAD), 21 22 cardiovascular disease (CVD), hypertension, hyper dyslipidemia, poor patient quality of life, and prolonged hospital admissions, which increase healthcare costs (8). 23

4

Tanzania guideline on hemodialysis recommends all patients have baseline measurements of their
blood sugar level and glycated hemoglobin (HbA1C) at the time of initiation of dialysis therapy.
HbA1c between 7% and 8%, fasting blood sugar <7.7mmol/L and postprandial blood sugar
11.1mmol/L are ideal targets, but epidemiological data recommends HbA1c from 6% to 8%, which
is associated with decreased mortality rates (9).

29 Several factors determine the glycemic control of diabetic patients with or without renal failure, which includes eating a healthy diet, physical exercise, blood transfusion, elevated blood urea 30 nitrogen (BUN), hemodialysis procedures, use of EPO, medication dose, and adherence (2,10). 31 32 Accumulation of uremic toxins among diabetic CKD patients compromises the quality of life due to increased risk of uremia, development of insulin resistance, decreased hepatic insulin 33 metabolism, uremic malnutrition, anaemia, gastritis, and increased risk of hospitalization due to 34 cognitive impairment (11,12). Therefore, adequately removing uremic toxins and other waste 35 products from the patient's blood through hemodialysis improves the quality of life and survival 36 rate of this patient group. 37

38 Despite the importance of glycemic control to diabetic CKD patients on maintenance dialysis, 39 there is limited data in sub-Saharan Africa, including Tanzania. Therefore, this study aimed to 40 evaluate the prevalence and determinants of poor glycemic control among diabetic CKD patients 41 attending hemodialysis centers in Tanzania.

42 Methods

43 Study design and settings

A cross-sectional study was conducted at selected hemodialysis centers in Tanzania from 1st March
to 30th June 2023. The enrolling sites were Muhimbili National Hospital (MNH) Upanga and

Mloganzila centers, CCBRT Hospital, Hubert Kairuki Hospital, TMJ Hospital, Hindu Mandal Hospital and Hindu Mandal Polyclinic, in Dar es Salaam region, Benjamin Mkapa Hospital found in Dodoma, NSK Hospital, Mt. Meru Hospital and Moyo Medicare specialized polyclinic in Arusha region and Bugando Medical Centre in Mwanza region. These centers were selected because they serve most patients from all parts of Tanzania, and they were confirmed to monitor patients' glycemic control using glycated hemoglobin assay. In addition, in all these centers, diabetic CKD patients are under the care of the nephrologists.

53 Study population

The study population consisted of diabetic CKD patients on maintenance hemodialysis at dialysiscenters in Tanzania.

56 Inclusion and exclusion criteria

The study included diabetic hemodialysis patients aged ≥ 18 years on maintenance hemodialysis for ≥ 3 months. It excluded critically ill patients who failed to express and consent themselves, those who voluntarily refused to be included, and those who had no HbA1c results within three months.

61 Sample size calculation

A sample size of 380 participants was obtained using a prevalence of 54% of poor glycemic control
in diabetes patients on hemodialysis conducted in Canada with a confidence level of 95% and a
margin of error of 5% (13).

65 Sampling strategy

Purposive sampling of regions and health facilities was used to enroll facilities providing dialysis
services and having the laboratory capacity to monitor glycemic control regularly. Then a
consecutive sampling technique was used to enroll patients in the selected facilities.

69 Data collection

Primary data such as sociodemographic characteristics, duration of diabetes and dialysis services, weight, height, and diabetes-related complications were collected from patients using a semistructured questionnaire. Secondary data such as the patients' medical history and type of investigations hemoglobin level (three months), glycated hemoglobin (one month), blood urea nitrogen (BUN) (three months), serum creatinine (one month), diabetic medications and other concomitant medications were collected from the patient's hospital records.

76 Data analysis

77 Data were analyzed using Statistical Package for Social Sciences (IBM-SPSS-version 23). Continuous variables were summarized using median and categorical variables were summarized 78 79 using frequency and percentages. Variables were selected based on their potential association with glycemic control. Hemoglobin (Hb) levels were graded as either anemic or non-anemic based on 80 Tanzania national dialysis guideline (Low Hb <10g/dl, Normal > 10g/dl). Average pre- and post-81 blood urea nitrogen (BUN) levels were used to compute urea reduction ratio (URR) as a maker for 82 dialysis adequacy and a dialysis adequacy was regarded as urea reduction ratio (URR) of >65%. 83 Furthermore, the Cockcroft and Gault equation was used to calculate estimated glomerular 84 85 filtration (eGFR), and eGFR of <15ml/minutes was regarded as kidney failure stage five (14).

Based on Tanzanian national dialysis guideline, HbA1c between 6% and 8% was considered adequate whereas HbA1c levels <6% and >8% were regarded as poor glycemic control. Prevalence ratios and their corresponding 95% confidence intervals (CI) were calculated by using univariate and multivariable regression models to show the determinants of poor glycemic control. Variables with p<0.1 on univariate analysis were considered for multivariate regression. P-value of <0.05 was considered statistically significant.

7

92 **Results**

93 Baseline socio-demographic characteristics of the study participants

- Among the study participants (n = 233), 70.4% were male, and the majority, 60.1%, were aged >
- 95 60 years with a median age of 63 years, IQR (56, 68). About 46% of participants were retirees,
- and 96.6% had insurance, **Table 1**.

97 Table 1: Baseline characteristics of the study participants (N = 233)

Variable	Frequency (n)	Percent (%)
Age group (years)		
18-60	93	39.9
>60	140	60.1
Median age in years (IQR)	63 (56, 68)	
Sex		
Male	164	70.4
Female	69	29.6
Marital status		
Married	203	87.1
Not married	30	12.9
Education Level		
No formal to primary education	76	32.6
Secondary education	42	18.0
Vocational training/certificate	24	10.3
Diploma	38	16.3
Degree/Masters/PhD	53	22.7
Occupation		
Not employed	41	17.6
Formal employment	43	18.5
Business	39	16.7
Student	2	0.9
Retired	108	46.4
History of cigarette smoking		
Ever smoked	60	25.8
Never smoked	173	74.2
History of alcohol use		
Ever drunk	154	66.1
Never drunk	79	33.9
Payment mode		

98	Insurance	225	96.6
	Cash	8	3.4

99 Clinical characteristics of the study participants

The study participants were comprised of 96.1% with type 2 diabetes, 56.2% with a family history 100 of diabetes, 99.1% hypertensive, and 26.6% stopped antihyperglycemic agents due to the 101 102 resolution of their hyperglycemia for more than one year. The majority (93.6%) of participants had CKD stage five, 88.4 were on dialysis three times per week, and 77.2% (n = 202) had attained 103 dialysis adequacy. In addition, 89.3% reported measuring blood glucose at home as a continuous 104 105 self-monitoring of diabetes, and 76% had developed diabetes-related complications such as peripheral neuropathy (72.1%), retinopathy (34.3%), micro/macrovascular (9.4%) and 106 gastroparesis (3.4%). About 47.2% of patients had an arterio-venous fistula (AV-Fistula) as 107 vascular access, Table 2. 108

Variable	Frequency (n)	Percent (%)	
Type of Diabetes			
Type 1	9	3.9	
Type 2	224	96.1	
Family history of diabetes			
Yes	131	56.2	
No	102	43.8	
History of hypertension			
Yes	231	99.1	
No	2	0.9	
Testing blood sugar at home			
Yes	208	89.3	
No	25	10.7	
Blood sugar readings (n = 208)			
Usually high	9	4.3	
Usually low	1	0.5	
Within goals	97	46.6	
Fluctuating between high and low	101	48.6	

109	Table 2: Clinical	characteristics of the study participants $(N = 233)$	
-----	-------------------	---	--

Experience episode of hypoglycemia		
Yes	125	53.6
No	108	46.4
BMI (kg/m ²)		
Underweight (< 18.5)	13	5.6
Normal weight (18.5 – 24.9)	118	50.6
Over weight (25.0 – 29.9)	75	32.2
Obesity (≥ 30.0)	27	11.6
When do hypoglycemia occurs $(n = 125)$		
During dialysis	2	1.6
After dialysis	4	3.2
At Home	119	95.2
Diabetic induced complications		
Yes	177	76.0
No	56	24.0

110

111 Prevalence of poor glycemic control

112 This study results revealed a prevalence of 55.4% of poor glycemic control among diabetic CKD

patients on maintenance dialysis, which is constituted by 27.04% of participants with HbA1c <6%

114 and 28.33% with HbA1c > 8%).

115 Determinants of glycemic state in diabetic hemodialysis patients

Patients who were still on antidiabetic medications had higher risk of poor glycemic control (HbA1c >8%) compared to those who stopped using medication due to resolution of hyperglycemia 2.16 (95% CI 1.06 – 4.41) p = 0.035. Patients attending dialysis sessions once to twice a week had a higher risk of poor glycemic control (HbA1c >8%) than those attending thrice a week 1.59 (95 CI 1.02 – 2.48), p = 0.040 (**Table 3**).

121 Table 3: Univariable and multivariable analysis for predictors associated with high HbA1c

122 >8% levels among diabetic_CKD patients on hemodialysis (n=170)

		Univariab	Univariable analysis		Multivariable analysis	
Variable	Category	cPR (95% CI)	P - value	aPR (95% CI)	P – value	

sh medication t on medication s thin goals	1ª 1.27(0.86 – 1.87) 1ª	0.083 0.034 0.226 0.017*	0.93 (0.46– 1.88) 2.16(1.06 – 4.41) 0.99 (0.66 – 1.49)	0.847 0.035 0.968
medication t on medication s thin goals	2.23 (1.06 – 4.69) 1 ^a 1.27(0.86 – 1.87) 1 ^a	0.226		
t on medication s thin goals	1ª 1.27(0.86 – 1.87) 1ª	0.226		
s thin goals	1.27(0.86 – 1.87) 1ª		0.99 (0.66 – 1.49)	0.968
thin goals	1ª		0.99 (0.66 – 1.49)	0.968
thin goals		0.017*		
-	0.56 (0.35 - 0.90	0.017*		
ictuating		0.017		
	1 ^a			
s	1.37 (0.92 – 2.06)	0.124	1.20 (0.81 – 1.79)	0.362
idequacy<65	1.34(0.86 - 2.07)	0.192*		
equacy >=65	1ª			
ce to twice	1.64 (1.09 – 2.45)	0.016	1.59(1.02 - 2.48)	0.040
rice	1 ^a			
th glucose	0.61 (0.39 - 0.97)	0.038	0.71 (0.45 – 1.11)	0.136
ucose free	1 ^a			
S	1.76 (0.97 – 3.21)	0.063	1.55 (0.87 – 2.78)	0.139
	1 a			
s	0.67 (0.46 - 0.97)	0.033	0.72(0.49 - 1.06)	0.094
	1 ^a			
S	1.51(0.95 - 2.39)	0.082	1.46 (0.92 – 2.33)	0.109
	1 ^a			
	dequacy<65 equacy >=65 ce to twice tice th glucose acose free	dequacy<65	dequacy<65	dequacy<65 $1.34(0.86 - 2.07)$ 0.192^* equacy >=65 1^a the to twice $1.64(1.09 - 2.45)$ 0.016 $1.59(1.02 - 2.48)$ fice 1^a the glucose $0.61(0.39 - 0.97)$ 0.038 $0.71(0.45 - 1.11)$ excess free 1^a 1.76(0.97 - 3.21) 0.063 $1.55(0.87 - 2.78)1^a0.67(0.46 - 0.97)$ 0.033 $0.72(0.49 - 1.06)1^a1.51(0.95 - 2.39)$ 0.082 $1.46(0.92 - 2.33)$

¹²³

Patients dialyzed using glucose-containing dialysates had a lower risk of poor glycemic control (HbA1c <6%) than those dialyzed with glucose-free dialysate 0.57 (95 CI 0.35 - 0.92), p = 0.020, and **Table 4**.

127 Table 4: Univariable and multivariable analysis for predictors associated with low HbA1c

128 <6% among diabetic-CKD patients on hemodialysis (n=167)

Variable	Category	Univariable	Univariable analysis		Multivariable analysis	
		cPR (95% CI)	P - value	aPR (95% CI)	P – value	
Marital status	Not married	0.47 (0.19 – 1.16)	0.103	0.61(0.27 - 1.36)	0.228	
	Married	1 ^a				

DM medication status	On medication	0.52 (0.36 - 0.76)	0.001	0.69 (0.37 – 1.29)	0.245
	Not on medication	1 a			
Insulin use	Yes	0.69 (0.39 – 1.21)	0.193	0.78 (0.39 – 1.53)	0.472
	No	1 a			
Episodes of hypoglycemia	Yes	0.78 (0.52 – 1.16)	0.213	0.88 (0.58 - 1.33)	0.547
	No				
Type of dialysate	With glucose	0.56 (0.36 - 0.87)	0.010	0.57 (0.35 - 0.92)	0.020
	Glucose free	1 ^a			
Sulfonylurea use	Yes	0.61 (0.38 - 0.97)	0.038	0.79 (0.42 - 1.49)	0.473
	No	1ª			
BT for past 3months	Yes	1.62 (0.77 – 3.4 1)	0.203	1.99 (0.98 - 4.05)	0.059
	No	1ª			
Duration on dialysis	<6.0	0.90 (0.32 - 2.54)	0.840	1.04(0.32 - 3.35)	0.953
(Months)					
	6.0 - 11.0	0.67(0.39 - 1.56)	0.149	074 (0.44 – 1.24)	0.254
	12.0 - 35.0	0.54 (0.32-0.91)	0.019	0.61 (0.36 – 1.01)	0.056
	36.0 - 59.0	0.66 (0.39 - 1.09)	0.108	0.65 (0.40 - 1.07)	0.088
	>= 60.0	1 ^a			
Calcium channel blocker use	Yes	0.72 (0.45–1.15)	0.167	0.62 (0.36 – 1.05)	0.074

129

130 **Discussion**

Our study aimed to determine the prevalence and determinants of poor glycemic control among diabetic CKD patients on maintenance hemodialysis. Significant findings of this study include a high prevalence (55.4%) of poor glycemic control among diabetic CKD patients in the population. It was observed that being on medication and attending dialysis sessions only once to twice a week were significantly associated with HbA1c >8% levels, while those who were dialyzed using glucose-containing dialysates were significantly associated with HbA1c <6% levels.

137The high prevalence of poor glycemic control in this study is in line with the findings from a study

138 conducted in Canada, which reported a prevalence of 54% among patients who developed diabetic-

related complications (13). Inadequate glycemic control with HbA1c >8% can contribute to the

development of diabetic-related complications such as diabetic neuropathy, retinopathy, and 140 macro and microvascular complications. This was also evident in our study, whereby 76% of 141 patients had diabetic-induced complications such as diabetic neuropathy, retinopathy and 142 macro/microvascular complications (13). The HbA1c <6% level is known to contribute to 143 increased mortality among diabetic CKD patients on maintenance hemodialysis. Two studies 144 145 conducted in London, United Kingdom, investigated the association between HbA1c and mortality rate and showed a J-shaped distribution of mortality risks. The studies concluded that both 146 deficient and high levels of HbA1c were related to increased mortality risks due to diabetic 147 complications and hypoglycemia, respectively (15,16). Further studies need to be conducted in 148 resource-constrained countries to investigate the risk of mortality in this group of patients. 149

This study showed that patients who were still on antidiabetic medication had a significantly higher risk of having HbA1c >8% levels compared to those who had their medications stopped due to the resolution of hyperglycemia. This might be due to insulin resistance associated with hyperuricemia in this patients' group and non-adherence to medication. Our study revealed that 33.9% of patients were non-adherent to medication, with about 55.2% of these having poor glycemic control. Our study findings correlate with the study conducted in Canada in which more patients who were on medication had poor glycemic control (13).

For the case of HbA1c <6%, our study showed that patients who were dialyzed using glucosecontaining dialysate had a lower risk of developing inadequate low glycemic control compared to those patients dialyzed without glucose-containing dialysate. This is because some of the blood glucose is lost during dialysis procedures due to hemofiltration (17). Our study findings correlate with the study conducted in India, which reported higher hypoglycemic episodes in patients dialyzed with glucose-free dialysates when compared with glucose-containing dialysate (18).

Despite some potential benefits of using glucose-free dialysates, such as reducing risks of bacterial infection, reducing skin autofluorescence (SAF), which is a marker of glycation end products (AGEs), mobilizing lipid to maintain normal blood glucose (19), in order to avoid the risk of hypoglycemic episodes and extremely low glucose levels, glucose-containing dialysates are recommended.

168 Moreover, the study showed that patients having once to twice hemodialysis sessions per week had a higher risk of HbA1c >8% compared to those with three sessions per week. Dialysis 169 frequency may be influenced by several factors but mainly the ability to pay for dialysis sessions. 170 171 Tanzania has more than 60 million people, but only 4.8 million people are covered with insurance (20). Though during the study period, 96.6% of patients were covered with insurance, previous 172 studies conducted in Tanzania have reported that the frequency of maintenance hemodialysis is 173 174 significantly influenced by the mode of payment, whereby patients covered by health insurance had higher adherence to dialysis sessions compared to non-insured patients (21,22) More studies 175 can be conducted to provide evidence on factors influencing dialysis frequency among insured 176 patients. 177

In this study, there were some limitations, including the reluctance of the participants to provide the required information and economic constraints among the study participants, making some of them fail to pay for the prescribed three-per-week hemodialysis sessions and HbA1c assay. The effective use of available resources, including hospital records and providing adequate information during the consenting process, was used to mitigate the limitations.

183 Conclusions

This study indicates that the prevalence of poor glycemic control in Tanzania is high amongdiabetic CKD patients on maintenance hemodialysis. Patients who had less than three dialysis

186	sessions per week had HbA1c >8%. We recommend tailored interventions to ensure that diabetic
187	CKD receive three dialysis sessions per week. Moreover, patients who were dialyzed using
188	glucose-free dialysates had poor low glycemic control, which emphasizes the significance of using
189	glucose-containing dialysates in our settings.
190	Competing Interest
191	The authors declare that there is no competing interest.
192	Funding
193	This was a self-funded study.
194	Authors' contribution
195	Authors contribution were as follows; EAM: Formulation of research idea, designed the research,
196	data collection, data analysis, interpretation of the results, manuscript writing, AM: Approved the
197	research idea and research design, interpretation of the results, review of the manuscript, final
198	approval of the manuscript, RM: Approved the research idea and research design, interpretation
199	of the results, review of the manuscript, final approval of the manuscript, DB: Approved the
200	research idea and research design, review of the manuscript, final approval of the manuscript.PK:
201	Data analysis, final approval of the manuscript.
202	Acknowledgement
203	The authors acknowledge the management of National Health Insurance Fund (NHIF), staff and
204	management of the data collection sites, Mr. Victor Njau, Mr. Devis Mhagama and staff of the
205	Department of Clinical Pharmacy and Pharmacology, MUHAS.
206	Declaration

207	Ethi	cs approval and consent to participate
208	This	study obtained ethical clearance from Muhimbili University of Health and Allied Sciences
209	(MU	HAS) institutional review board (Certificate number: MUHA-REC-02-2023-1533). In
210	addit	tion, permission to conduct this study in the selected facilities was sought from each hospital
211	mana	agement. Written informed consent was obtained from each participant.
212	Con	sent for publication
213	Nota	applicable.
214	Refe	erences
215	1.	Hassanein M, Shafi T. Assessment of glycemia in chronic kidney disease. Vol. 20, BMC
216		Medicine. BioMed Central Ltd; 2022.
217	2.	Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K. Updates on
218		the management of diabetes in dialysis patients. Semin Dial. 2014;27(2):135-45.
219	3.	Archives of Clinical Nephrology Management of type 2 Diabetes in patients with Chronic
220		Kidney Disease. 2017; 3:47–52.
221	4.	Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, et al. Impact of
222		glycemic control on survival of diabetic patients on chronic regular hemodialysis: A 7-year
223		observational study. Diabetes Care. 2006;29(7):1496-500.
224	5.	Neumiller JJ, Alicic RZ, Tuttle KR. Therapeutic considerations for antihyperglycemic
225		agents in diabetic kidney disease. Journal of the American Society of Nephrology.
226		2017;28(8):2263–74.

227	6.	Harris SB, Ekoé JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in
228		the Canadian primary care setting (results of the diabetes in Canada evaluation study).
229		Diabetes Res Clin Pract. 2005;70(1):90–7.
230	7.	Kamuhabwa AR, Charles E. Predictors of poor glycemic control in type 2 diabetic patients
231		attending public hospitals in Dar es Salaam. Drug Healthc Patient Saf. 2014 Oct 24;6:155-
232		65.
233	8.	Rwegerera GM. Adherence to anti-diabetic drugs among patients with Type 2 diabetes
234		mellitus at Muhimbili National Hospital, Dar es Salaam, Tanzania- A cross-sectional study.
235		2014; 8688:1–9.
236	9.	Tanzania National guidelines for dialysis services in Tanzania. 2019;1–54.
237	10.	Nakamura Y. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World
238		J Diabetes. 2015;6(6):840.
239	11.	Somji SS, Ruggajo P, Moledina S. Adequacy of Hemodialysis and Its Associated Factors
240		among Patients Undergoing Chronic Hemodialysis in Dar es Salaam, Tanzania. Int J
241		Nephrol. 2020;2020.
242	12.	Frankel A, Karalliede J, Montero RM, Pokrajac A, Winocour P, Fogarty D, et al. Clinical
243		practice guidelines for management of hyperglycaemia in adults with diabetic kidney
244		disease Writing group members Debasish Banerjee MD FRCP Indranil Dasgupta DM
245		FRCP Correspondence Citation for this document. 2021.
246	13.	Tascona DJ, Morton AR, Toffelmire EB, Holland DC, Iliescu EA. Adequacy of glycemic
247		control in hemodialysis patients with diabetes. Diabetes Care. 2006;29(10):2247-51.

- 14. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney
 Disease. Kidney Int. 2020 Oct 1;98(4): S1–115.
- Forbes A, Murrells T, Mulnier H, Sinclair AJ. Mean HbA 1c , HbA 1c variability, and
 mortality in people with diabetes aged 70 years and older: a retrospective cohort study.
 Lancet Diabetes Endocrinol. 2018 Jun 1;6(6):476–86.
- Critchley JA, Carey IM, Harris T, DeWilde S, Cook DG. Variability in glycated hemoglobin
 and risk of poor outcomes among people with type2diabetesinalargeprimary care cohort
 study. Diabetes Care. 2019 Dec 1;42(12):2237–46.
- 17. Burmeister JE, Campos JF, Miltersteiner D da R. Efeito de diferentes níveis de glicose no
 dialisato sobre o risco de hipoglicemia durante hemodiálise em pacientes diabéticos [Effect
 of different levels of glucose in the dialysate on the risk of hypoglycaemia during
 hemodialysis in diabetic patients]. J Bras Nefrol. 2012;34(4):323–7.
- Padmanabhan A, Velayudham B, Vijaykumar N, Allauddin S. Evaluation of glycemic status
 during the days of hemodialysis using dialysis solutions with and without glucose. Saudi J
 Kidney Dis Transpl. 2018;29(5):1021–7.
- Li M, Li Y, Lv J, Xu H, Wu X, Wen W, et al. The effects of glucose-free and glucosecontaining dialysate during dialysis in MHD patients: a prospective cross-over study.
 Perfusion (United Kingdom). 2023 Jan 1;38(1):178–85.
- 266 20. NHIF-Annual Report 2021/22.

267	21.	Mohamedi S, Mosha IH. Hemodialysis Therapy Adherence and Contributing Factors
268		among End-Stage Renal Disease Patients at Muhimbili National Hospital, Dar es Salaam,
269		Tanzania. Kidney and Dialysis. 2022 Mar 21;2(1):123–30.
270	22.	Meremo AJ, Ngilangwa DP, Mwashambwa MY, Masalu MB, Kapinga J, Tagalile R, et al.
271		Challenges and outcomes of haemodialysis among patients presenting with kidney diseases
272		in Dodoma, Tanzania. BMC Nephrol. 2017 Jul 4;18(1).
273		

274